Application of signal pathway signal inhibitor or protein synthesis inhibitor or madecassic acid in preparation of drug for treating osteoporosis

An application of a signal pathway signal inhibitor or a protein synthesis inhibitor or a madecassic acid in preparation of a drug for treating osteoporosis is disclosed. The madecassic acid inhibitsan expression of key protein-NFATc1 required for effect performance of osteoclasts through NF-[kappa]B, calcium/calmodulin-dependent kinase and MAPK three signal transduction pathways, and RANKL-induced osteoclast generation is ultimately inhibited. The application first describes and demonstrates that the madecassic acid has a satisfactory therapeutic effect on osteoporosis caused by estrogen deficiency, suggests that a natural compound madecassic acid extracted from Chinese herbal medicine has good application prospects in prevention and treatment of the osteoporosis, and provides a new option and a drug development idea for the treatment of the osteoporosis.